<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037881</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 29102-C21</org_study_id>
    <secondary_id>EudraCT Number 2009-013792-22</secondary_id>
    <nct_id>NCT01037881</nct_id>
  </id_info>
  <brief_title>LEO 29102 Cream in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Proof of Concept and Dose Finding Study, Investigating Treatment Efficacy of LEO 29102 Cream, LEO 29102 Cream Vehicle, and Elidel® Cream 10 mg/g, After Cutaneous Administration Twice Daily for 4 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with
      vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment
      regimen in mild to moderate atopic dermatitis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>Baseline (Day 0) and end of treatment (Day 28)</time_frame>
    <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe
The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Were Symptom Free Responders (LOCF)</measure>
    <time_frame>At end of treatment (Day 28)</time_frame>
    <description>The IGA (Investigator's global assessment) of disease severity on the body (trunk and limbs excluding the hands) was assessed based on visual evaluation by use of the following definitions of severity:
0. Clear - no inflammatory signs of AD
Almost clear - just perceptible erythema, and just perceptible papulation/infiltration
Mild - mild erythema, and mild papulation/infiltration
Moderate - moderate erythema, and moderate papulation/infiltration
Severe - severe erythema, and-severe papulation/infiltration
Very severe - severe erythema, and severe papulation/infiltration with oozing/crusting.
Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Assessment of Pruritus on Trunk and Limbs</measure>
    <time_frame>At end of treatment (Day 28)</time_frame>
    <description>Participants' assessment of pruritus on trunk and limbs was assessed at end of treatment by use of the scale below.
Absent - no itching
Mild - occasional, slight itching
Moderate - constant or intermittent itching which is not disturbing sleep
Severe - intolerable itching which is disturbing sleep
The assessment was based on the average degree of pruritus over the last 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Overall Assessment of Disease Severity</measure>
    <time_frame>At end of treatment (Day 28)</time_frame>
    <description>Participants' overall assessment of disease severity on trunk and limbs (excluding the hands) was assessed at end of treatment by use of the following scale: clear, very mild, mild, moderate, severe.
The assessment was based on the condition of the disease at the time of the evaluation and not in relation to the condition at a previous visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Were Symptom Free Responders by Visit</measure>
    <time_frame>At Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21) and end of treatment (Day 28)</time_frame>
    <description>Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) according to Investigator's global assessment of disease severity on trunk and limbs at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline by Visit</measure>
    <time_frame>Baseline and at Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21)</time_frame>
    <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 29102 0.03 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 0.1 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 0.3 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 1.0 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 2.5 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elidel® cream (pimecrolimus) 10 mg/g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>LEO 29102 0.03 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 0.1 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 0.3 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 1.0 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 2.5 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 cream vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elidel®</intervention_name>
    <description>comparison</description>
    <arm_group_label>Elidel® cream (pimecrolimus) 10 mg/g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka

          -  IGA assessment scored as mild (2) to moderate (3) atopic dermatitis

          -  Treatment lesions located on the trunk and limbs

          -  Treatment lesions involving 3% to 10% of the total body surface area

          -  Patients of either gender between 18 years and 65 years of age

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks
             prior to randomisation

          -  Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks
             prior to randomisation

          -  Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week
             prior to randomisation

          -  Use of topical or systemic antibiotics within 2 weeks prior to randomisation

          -  PUVA or UVB therapy within 4 weeks prior to randomisation

          -  Clinical infection (viral, fungal or bacterial) on the treatment area

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Patients with history of an immunocompromised disease (e.g., lymphoma, HIV,
             Wiskott-Aldrich Syndrome)

          -  Patients with concomitant serious disease (e.g., cancer) which might affect the AD
             treatment in this trial

          -  Females who are pregnant or are breast feeding

          -  Females intending to temporarily or permanently stop their hormonal contraceptive
             regime during and up to one month post study termination visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakari Reitamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie, Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <results_first_submitted>August 8, 2018</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants received investigational medicinal products for up to 4-weeks followed by a 28 day follow-up period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 29102 Vehicle</title>
          <description>LEO 29102 cream vehicle applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total body surface area (BSA) for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an investigator's global assessment [IGA] of 0 or 1, i.e. clear or almost clear of symptoms) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Visit 6 (Day 56). The participants had to have study medication dispensed and should restart treatment if required, based on the participant's own judgement. More than one discontinuation/restart cycle was allowed.</description>
        </group>
        <group group_id="P2">
          <title>LEO 29102 0.03 mg/g</title>
          <description>LEO 29102 0.03 mg/g cream applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1, i.e. clear or almost clear of symptoms) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participants had to have study medication dispensed and should restart treatment if required, based on the participant’s own judgement. More than one discontinuation/restart cycle was allowed.</description>
        </group>
        <group group_id="P3">
          <title>LEO 29102 0.1 mg/g</title>
          <description>LEO 29102 0.1 mg/g cream applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participants had to have study medication dispensed and should restart treatment if required, based on the participant's own judgement. More than one discontinuation/restart cycle was allowed.</description>
        </group>
        <group group_id="P4">
          <title>LEO 29102 0.3 mg/g</title>
          <description>LEO 29102 0.3 mg/g cream applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participants had to have study medication dispensed and should restart treatment if required, based on the participant’s own judgement. More than one discontinuation/restart cycle was allowed.</description>
        </group>
        <group group_id="P5">
          <title>LEO 29102 1.0 mg/g</title>
          <description>LEO 29102 1.0 mg/g cream applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participant had to have study medication dispensed and should restart treatment if required, based on the participant’s own judgement. More than one discontinuation/restart cycle was allowed.
Participants were not randomized to this treatment until the results from the hormone screen blood samples from at least 10 participants in each of the five initial treatment arms (LEO 29102 0.03 mg/g cream, 0.1 mg/g cream,0.3 mg/g cream, cream vehicle, and Elidel®) were available and no safety concerns had been raised.</description>
        </group>
        <group group_id="P6">
          <title>LEO 29102 2.5 mg/g</title>
          <description>LEO 29102 2.5 mg/g cream applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks. Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participants had to have study medication dispensed and should restart treatment if required, based on the participant’s own judgement. More than one discontinuation/restart cycle was allowed.
Participants were not randomized to this treatment until the results from the hormone screen blood samples from at least 10 participants in each of the five initial treatment arms (LEO 29102 0.03 mg/g cream, 0.1 mg/g cream,0.3 mg/g cream, cream vehicle, and Elidel®) were available and no safety concerns had been raised.</description>
        </group>
        <group group_id="P7">
          <title>Elidel® 10 mg/g</title>
          <description>Elidel® applied topically twice daily - in the morning and in the evening - on a total area of 3-10% of the total BSA for up to 4 weeks.
Participants who were evaluated by the investigator to be symptom-free (as defined by an IGA of 0 or 1) at any of Visits 2(Day 7), 3(Day 14) or 4(Day 21) could stop treatment at the investigator’s discretion. They were to remain in the study and attend all visits up to and including Day 56. The participants had to have study medication dispensed and should restart treatment if required, based on the participant’s own judgement. More than one discontinuation/restart cycle was allowed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="30"/>
                <participants group_id="P7" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="27"/>
                <participants group_id="P7" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 29102 Vehicle</title>
          <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>LEO 29102 0.03 mg/g</title>
          <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>LEO 29102 0.1 mg/g</title>
          <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>LEO 29102 0.3 mg/g</title>
          <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>LEO 29102 1.0 mg/g</title>
          <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B6">
          <title>LEO 29102 2.5 mg/g</title>
          <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B7">
          <title>Elidel® 10 mg/g</title>
          <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="29"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="25"/>
            <count group_id="B8" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="14.0"/>
                    <measurement group_id="B2" value="36.2" spread="14.4"/>
                    <measurement group_id="B3" value="34.9" spread="11.8"/>
                    <measurement group_id="B4" value="38.3" spread="12.6"/>
                    <measurement group_id="B5" value="32.0" spread="10.0"/>
                    <measurement group_id="B6" value="35.5" spread="13.7"/>
                    <measurement group_id="B7" value="29.9" spread="8.8"/>
                    <measurement group_id="B8" value="35.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation Carried Forward [LOCF])</title>
        <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe
The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
        <time_frame>Baseline (Day 0) and end of treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 week</description>
          </group>
          <group group_id="O7">
            <title>Elidel® 10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation Carried Forward [LOCF])</title>
          <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe
The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="6.85"/>
                    <measurement group_id="O2" value="-2.13" spread="3.00"/>
                    <measurement group_id="O3" value="-1.09" spread="5.81"/>
                    <measurement group_id="O4" value="-2.86" spread="2.99"/>
                    <measurement group_id="O5" value="-2.41" spread="2.38"/>
                    <measurement group_id="O6" value="-2.50" spread="3.28"/>
                    <measurement group_id="O7" value="-3.30" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.60</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.30</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.84</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Active treatment minus vehicle, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.47</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>3.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>LEO 29102 treatment minus Elidel, adjusted for the effect of (pooled) country.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>ANOVA</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Were Symptom Free Responders (LOCF)</title>
        <description>The IGA (Investigator's global assessment) of disease severity on the body (trunk and limbs excluding the hands) was assessed based on visual evaluation by use of the following definitions of severity:
0. Clear - no inflammatory signs of AD
Almost clear - just perceptible erythema, and just perceptible papulation/infiltration
Mild - mild erythema, and mild papulation/infiltration
Moderate - moderate erythema, and moderate papulation/infiltration
Severe - severe erythema, and-severe papulation/infiltration
Very severe - severe erythema, and severe papulation/infiltration with oozing/crusting.
Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) at the end of treatment.</description>
        <time_frame>At end of treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O7">
            <title>Elidel® 10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Were Symptom Free Responders (LOCF)</title>
          <description>The IGA (Investigator's global assessment) of disease severity on the body (trunk and limbs excluding the hands) was assessed based on visual evaluation by use of the following definitions of severity:
0. Clear - no inflammatory signs of AD
Almost clear - just perceptible erythema, and just perceptible papulation/infiltration
Mild - mild erythema, and mild papulation/infiltration
Moderate - moderate erythema, and moderate papulation/infiltration
Severe - severe erythema, and-severe papulation/infiltration
Very severe - severe erythema, and severe papulation/infiltration with oozing/crusting.
Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) at the end of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Assessment of Pruritus on Trunk and Limbs</title>
        <description>Participants' assessment of pruritus on trunk and limbs was assessed at end of treatment by use of the scale below.
Absent - no itching
Mild - occasional, slight itching
Moderate - constant or intermittent itching which is not disturbing sleep
Severe - intolerable itching which is disturbing sleep
The assessment was based on the average degree of pruritus over the last 24 hours.</description>
        <time_frame>At end of treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O7">
            <title>Elidel®10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Assessment of Pruritus on Trunk and Limbs</title>
          <description>Participants' assessment of pruritus on trunk and limbs was assessed at end of treatment by use of the scale below.
Absent - no itching
Mild - occasional, slight itching
Moderate - constant or intermittent itching which is not disturbing sleep
Severe - intolerable itching which is disturbing sleep
The assessment was based on the average degree of pruritus over the last 24 hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Overall Assessment of Disease Severity</title>
        <description>Participants' overall assessment of disease severity on trunk and limbs (excluding the hands) was assessed at end of treatment by use of the following scale: clear, very mild, mild, moderate, severe.
The assessment was based on the condition of the disease at the time of the evaluation and not in relation to the condition at a previous visit.</description>
        <time_frame>At end of treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O7">
            <title>Elidel® 10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Overall Assessment of Disease Severity</title>
          <description>Participants' overall assessment of disease severity on trunk and limbs (excluding the hands) was assessed at end of treatment by use of the following scale: clear, very mild, mild, moderate, severe.
The assessment was based on the condition of the disease at the time of the evaluation and not in relation to the condition at a previous visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clear</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Were Symptom Free Responders by Visit</title>
        <description>Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) according to Investigator's global assessment of disease severity on trunk and limbs at the end of treatment.</description>
        <time_frame>At Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21) and end of treatment (Day 28)</time_frame>
        <population>Occurrences of early withdrawal, non-compliance, prohibited medication, missing application of study medication and participants missing visits resulted in not all participants being analyzed at all visits.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O7">
            <title>Elidel® 10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Were Symptom Free Responders by Visit</title>
          <description>Symptom free responders were defined as an IGA of 0 (Clear) or 1 (Almost clear) according to Investigator's global assessment of disease severity on trunk and limbs at the end of treatment.</description>
          <population>Occurrences of early withdrawal, non-compliance, prohibited medication, missing application of study medication and participants missing visits resulted in not all participants being analyzed at all visits.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Day 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 28)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline by Visit</title>
        <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
        <time_frame>Baseline and at Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21)</time_frame>
        <population>Data was tabulated using an observed cases approach and therefore only contains data from participants who attended the specific visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 29102 Vehicle</title>
            <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 29102 0.03 mg/g</title>
            <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LEO 29102 0.1 mg/g</title>
            <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LEO 29102 0.3 mg/g</title>
            <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>LEO 29102 1.0 mg/g</title>
            <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>LEO 29102 2.5 mg/g</title>
            <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
          <group group_id="O7">
            <title>Elidel® 10 mg/g</title>
            <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline by Visit</title>
          <description>The EASI is a composite score based on the evaluation of four characteristic atopic dermatitis (AD) signs and symptoms; erythema, oedema/induration/papulation, excoriation and lichenification together with the area involved.
For each body region, the investigator rated four clinical signs of AD using the following severity scale:
0 = none/absent
= mild
= moderate
= severe The EASI score ranges from 0-12, a higher score equals a worse outcome. Baseline was defined as Day 0. Mean values in table are least squares mean adjusted for the effect of (pooled) country.</description>
          <population>Data was tabulated using an observed cases approach and therefore only contains data from participants who attended the specific visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="5.27"/>
                    <measurement group_id="O2" value="-1.26" spread="1.72"/>
                    <measurement group_id="O3" value="-0.93" spread="1.82"/>
                    <measurement group_id="O4" value="-1.43" spread="2.53"/>
                    <measurement group_id="O5" value="-1.64" spread="1.71"/>
                    <measurement group_id="O6" value="-1.48" spread="2.28"/>
                    <measurement group_id="O7" value="-1.21" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Day 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="2.77"/>
                    <measurement group_id="O2" value="-1.48" spread="2.19"/>
                    <measurement group_id="O3" value="-1.30" spread="2.28"/>
                    <measurement group_id="O4" value="-2.19" spread="3.14"/>
                    <measurement group_id="O5" value="-1.67" spread="2.15"/>
                    <measurement group_id="O6" value="-1.52" spread="3.17"/>
                    <measurement group_id="O7" value="-1.82" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 21)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="4.18"/>
                    <measurement group_id="O2" value="-1.76" spread="2.67"/>
                    <measurement group_id="O3" value="-0.89" spread="5.94"/>
                    <measurement group_id="O4" value="-2.21" spread="3.27"/>
                    <measurement group_id="O5" value="-1.90" spread="2.57"/>
                    <measurement group_id="O6" value="-2.53" spread="2.18"/>
                    <measurement group_id="O7" value="-2.16" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline (Day 0) to Day 28±3 (end of treatment) and follow-up phase (from end of treatment to Day 56±4)</time_frame>
      <desc>The Safety Analysis Set only consisted of participants who applied study medication. One participant from the LEO 29102 1.0 mg/g arm, did not apply any study medication and was therefore excluded from the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>LEO 29102 Cream Vehicle - Treatment Phase</title>
          <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>LEO 29102 0.03 mg/g Cream - Treatment Phase</title>
          <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>LEO 29102 0.1 mg/g Cream - Treatment Phase</title>
          <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>LEO 29102 0.3 mg/g Cream - Treatment Phase</title>
          <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E5">
          <title>LEO 29102 1.0 mg/g Cream - Treatment Phase</title>
          <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E6">
          <title>LEO 29102 2.5 mg/g Cream - Treatment Phase</title>
          <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E7">
          <title>Elidel® Cream (Pimecrolimus) 10 mg/g - Treatment Phase</title>
          <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E8">
          <title>LEO 29102 Cream Vehicle - Follow-up Phase</title>
          <description>Treatment with LEO 29102 cream vehicle twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E9">
          <title>LEO 29102 0.03 mg/g Cream - Follow-up Phase</title>
          <description>Treatment with LEO 29102 0.03 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E10">
          <title>LEO 29102 0.1 mg/g Cream - Follow-up Phase</title>
          <description>Treatment with LEO 29102 0.1 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E11">
          <title>LEO 29102 0.3 mg/g Cream - Follow-up Phase</title>
          <description>Treatment with LEO 29102 0.3 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E12">
          <title>LEO 29102 1.0 mg/g Cream - Follow-up Phase</title>
          <description>Treatment with LEO 29102 1.0 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E13">
          <title>LEO 29102 2.5 mg/g Cream - Follow-up Phase</title>
          <description>Treatment with LEO 29102 2.5 mg/g cream twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
        <group group_id="E14">
          <title>Elidel® 10 mg/g - Follow-up Phase</title>
          <description>Treatment with Elidel® twice daily - in the morning and in the evening - for up to 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Herpes simplex ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestatic pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigators’ right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

